Development and validation of a risk score to predict QT interval prolongation in hospitalized patients
- PMID: 23716032
- PMCID: PMC3788679
- DOI: 10.1161/CIRCOUTCOMES.113.000152
Development and validation of a risk score to predict QT interval prolongation in hospitalized patients
Erratum in
- Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57
Abstract
Background: Identifying hospitalized patients at risk for QT interval prolongation could lead to interventions to reduce the risk of torsades de pointes. Our objective was to develop and validate a risk score for QT prolongation in hospitalized patients.
Methods and results: In this study, in a single tertiary care institution, consecutive patients (n=900) admitted to cardiac care units comprised the risk score development group. The score was then applied to 300 additional patients in a validation group. Corrected QT (QTc) interval prolongation (defined as QTc>500 ms or an increase of >60 ms from baseline) occurred in 274 (30.4%) and 90 (30.0%) patients in the development group and validation group, respectively. Independent predictors of QTc prolongation included the following: female (odds ratio, 1.5; 95% confidence interval, 1.1-2.0), diagnosis of myocardial infarction (2.4 [1.6-3.9]), septic shock (2.7 [1.5-4.8]), left ventricular dysfunction (2.7 [1.6-5.0]), administration of a QT-prolonging drug (2.8 [2.0-4.0]), ≥2 QT-prolonging drugs (2.6 [1.9-5.6]), or loop diuretic (1.4 [1.0-2.0]), age >68 years (1.3 [1.0-1.9]), serum K⁺ <3.5 mEq/L (2.1 [1.5-2.9]), and admitting QTc >450 ms (2.3; confidence interval [1.6-3.2]). Risk scores were developed by assigning points based on log odds ratios. Low-, moderate-, and high-risk ranges of 0 to 6, 7 to 10, and 11 to 21 points, respectively, best predicted QTc prolongation (C statistic=0.823). A high-risk score ≥11 was associated with sensitivity=0.74, specificity=0.77, positive predictive value=0.79, and negative predictive value=0.76. In the validation group, the incidences of QTc prolongation were 15% (low risk); 37% (moderate risk); and 73% (high risk).
Conclusions: A risk score using easily obtainable clinical variables predicts patients at highest risk for QTc interval prolongation and may be useful in guiding monitoring and treatment decisions.
Keywords: QT interval; electrocardiography; predictors; risk factors; torsades de pointes.
Figures
Similar articles
-
Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients.Circ Cardiovasc Qual Outcomes. 2014 May;7(3):381-90. doi: 10.1161/CIRCOUTCOMES.113.000651. Epub 2014 May 6. Circ Cardiovasc Qual Outcomes. 2014. PMID: 24803473 Free PMC article.
-
Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.Drug Saf. 2012 Jun 1;35(6):459-70. doi: 10.2165/11598160-000000000-00000. Drug Saf. 2012. PMID: 22612851
-
Predictive Validity of a QTc Interval Prolongation Risk Score in the Intensive Care Unit.Pharmacotherapy. 2020 Jun;40(6):492-499. doi: 10.1002/phar.2400. Epub 2020 May 7. Pharmacotherapy. 2020. PMID: 32259316
-
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.Curr Med Res Opin. 2013 Dec;29(12):1719-26. doi: 10.1185/03007995.2013.840568. Epub 2013 Sep 23. Curr Med Res Opin. 2013. PMID: 24020938 Review.
-
Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.Drugs Aging. 2009;26(12):997-1012. doi: 10.2165/11318880-000000000-00000. Drugs Aging. 2009. PMID: 19929028 Review.
Cited by
-
A case-control study on the clinical characteristics of granisetron-related arrhythmias and the development of a predictive nomogram.Int J Clin Pharm. 2024 Feb 28. doi: 10.1007/s11096-024-01703-3. Online ahead of print. Int J Clin Pharm. 2024. PMID: 38416350
-
Developing a Model for Quantifying QTc-Prolongation Risk to Enhance Medication Safety Assessment: A Retrospective Analysis.J Pers Med. 2024 Jan 31;14(2):172. doi: 10.3390/jpm14020172. J Pers Med. 2024. PMID: 38392605 Free PMC article.
-
Impact of an inpatient pharmacist-driven renal dosing policy on order verification time and patient safety.SAGE Open Med. 2024 Feb 19;12:20503121241233223. doi: 10.1177/20503121241233223. eCollection 2024. SAGE Open Med. 2024. PMID: 38379810 Free PMC article.
-
Assessment of Drug-Induced QTc Prolongation in Mental Health Practice: Validation of an Evidence-Based Algorithm.Risk Manag Healthc Policy. 2023 Oct 13;16:2113-2124. doi: 10.2147/RMHP.S426591. eCollection 2023. Risk Manag Healthc Policy. 2023. PMID: 37854638 Free PMC article.
-
Drug-drug interactions between COVID-19 therapeutics and antiretroviral treatment: the evidence to date.Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(11):795-806. doi: 10.1080/17425255.2023.2267970. Epub 2023 Nov 17. Expert Opin Drug Metab Toxicol. 2023. PMID: 37800561 Review.
References
-
- Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891–899. - PubMed
-
- Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425–430. - PubMed
-
- Tisdale JE. Ventricular arrhythmias. In: Tisdale JE, Miller DA, editors. Drug-induced diseases. Prevention, detection and management. 2nd ed. Bethesda: American Society of Health-System Pharmacists; 2010. pp. 485–515.
-
- Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. on behalf of the American heart Association Acute Cardiac care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–947. - PMC - PubMed
-
- Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84:1136–1144. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
